CapsoVision is heading to IPO with a bold promise: to revolutionize gastrointestinal diagnostics using AI-powered capsule endoscopy. The company’s flagship, CapsoCam Plus, offers a non-invasive, sedation-free alternative to traditional scopes—an appealing upgrade for patients and physicians alike.
The IPO seeks to raise $27.5M to scale production, complete regulatory hurdles (including for its colon-targeting CapsoCam Colon), and compete in the $6.87B GI diagnostics market. But giants like Abbott and Fujifilm aren’t sitting still, and FDA approval remains a major milestone to watch.